Cover: Mapping Pathways

Mapping Pathways

Developing evidence-based, people-centred strategies for the use of antiretrovirals as prevention

Published Jun 19, 2013

by Molly Morgan Jones

with Jim Pickett, Joanna Chataway, James Swartz, Ohid Yaqub, Philip Smith, Kartika Palar, Jessica Terlikowski, Daniella Mark, William McColl, Petal Hackett, et al.

Download eBook for Free

Full Document

FormatFile SizeNotes
PDF file 6.3 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.

Summary Only

FormatFile SizeNotes
PDF file 0.1 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.

Research Questions

  1. What does the scientific literature say about ARV-based prevention strategies?
  2. What do policymakers say about their concerns and evidence needs in the face of rapid scientific advances?
  3. What do the experts say about patient-related, social, economic and clinical delivery conditions?
  4. What are the 'grassroots' perspectives on the practical challenges of implementing strategies in different contexts?

Mapping Pathways is a multinational project to develop and nurture a research-driven, community-led global understanding of the emerging evidence base around the adoption of antiretroviral (ARV)-based prevention strategies to end the HIV/AIDS epidemic. The project is based on the premise that the current array of prevention options is not sufficient; new pathways to prevention, based on enhanced assessment and analysis of likely impact, are needed to address new infections adequately.

ARVs are opening up new options for HIV prevention, such as 'treatment as prevention' (often referred to as 'TLC+' [testing, linkage to care], plus treatment), microbicides, oral pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). There are multifaceted challenges associated with these new prevention strategies related to access, cost, behavioural and health impacts, and implementation.

Mapping Pathways: Developing evidence-based, people-centred strategies for the use of antiretrovirals as prevention is designed to support critical thinking and development of a new research agenda for the analysis of multiple policy options — the pathways — that should be considered by prevention planners, programmers and funders when addressing the opportunities and challenges of the new ARV paradigm.

Key Findings

  • Structural factors such as cost and access are as important as individual behaviours.
  • Policymakers and communities need more information to develop successful local strategies.
  • Local context shapes perception: the same scientific data will be viewed and interpreted differently by stakeholders in different countries and groups.
  • The science is dynamic and fast-changing. Providing insight from diverse communities and stakeholders will enrich policies to ensure that ARVs can reach their prevention potential at local and global levels.

Author Statement

Research conducted by

The research described in this report was sponsored by Merck & Co. and conducted by RAND Europe.

This report is part of the RAND research report series. RAND reports present research findings and objective analysis that address the challenges facing the public and private sectors. All RAND reports undergo rigorous peer review to ensure high standards for research quality and objectivity.

This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.